Itrapeak Capsule contains Itraconazole 100 mg, a broad-spectrum triazole antifungal agent indicated for the treatment of various fungal infections. Itraconazole exerts its antifungal effect by inhibiting the cytochrome P450-dependent enzyme lanosterol 14-α-demethylase, which is essential for ergosterol synthesis, a key component of fungal cell membranes. This disruption leads to increased membrane permeability and ultimately fungal cell death. Itrapeak Capsule is commonly prescribed for the management of systemic and superficial mycoses, including blastomycosis, histoplasmosis, aspergillosis, onychomycosis, and candidiasis. It is effective against a wide range of pathogenic fungi, including Candida species, Aspergillus species, and dermatophytes. The recommended dosage and duration of therapy depend on the type and severity of the infection, patient response, and clinical judgment. Itrapeak should be administered with food to enhance absorption. Caution is advised in patients with hepatic impairment, congestive heart failure, or those taking concomitant medications metabolized via the cytochrome P450 system due to potential drug interactions. Adverse effects may include gastrointestinal disturbances, headache, dizziness, and elevated liver enzymes. Regular monitoring of liver function tests is recommended during prolonged therapy. Itrapeak Capsule should be used under medical supervision to ensure safe and effective treatment outcomes.